July 6, 2015Akcea Therapeutics Receives Orphan Drug Designation from the US FDA for Volanesorsen (ISIS-APOCIII Rx) for the Treatment of Familial Chylomicronemia Syndrome
June 30, 2015Webcast Alert: Corporate Presentation at the 2015 Isis Pharmaceuticals Annual Stockholder Meeting
2015 Stockholder Annual Meeting
Isis Scientists Identify a New Antisense Drug Candidate for the Treatment of Patients with the Autosomal Dominant Retinitis Pigmentosa
We have numerous ongoing clinical trials designed to evaluate our drugs in a variety of health conditions. More »
No upcoming events at this time...